Literature DB >> 25081715

TLR9 expression in uterine cervical lesions of Uyghur women correlate with cervical cancer progression and selective silencing of human papillomavirus 16 E6 and E7 oncoproteins in vitro.

Yi Hao1, Jian-Ling Yuan, Abulizi Abudula, Axiangu Hasimu, Nafeisha Kadeer, Xia Guo.   

Abstract

BACKGROUND: Cervical cancer is listed as one of high-incidence endemic diseases in Xinjiang. Our study aimed to evaluate the expression of TLR9 in uterine cervical tissues of Uyghur women and examine associations with clinicopathological variables. We further characterized the direct effects of TLR9 upon the selective silencing of human papillomavirus (HPV) E6 and E7 oncoprotein expression in HPV 16-positive human cervical carcinoma cells treated with siRNA in vitro.
MATERIALS AND METHODS: Immunohistochemistry was applied to evaluate TLR9 expression in 97 formalin-fixed paraffin-embedded cervical samples from Uyghur women; 32 diagnosed with cervical squamous cell carcinomas (CSCC) , 14 with low-grade cervical intraepithelial neoplasias (CINI), 10 medium-grade (CINII), 24 high-grade (CINIII), and 17 chronic cervicitis. BLOCK-iTTM U6 RNAi Entry Vector pENTRTM/U6-E6 and E7 was constructed and transfected the entry clone directly into the mammalian cell line 293FT. Then the HPV 16-positive SiHa human cervical carcinoma cell line was infected with RNAi recombinant lentivirus. RT-PCR and Western blotting were used to determine the expression of TLR9 in both SiHa and HPV 16 E6 and E7 silenced SiHa cells.
RESULTS: Immunohistochemical staining showed that TLR9 expression was undetectable (88.2%) or weak (11.8%) in chronic cervicitis tissues. However, variable staining was observed in the basal layer of all normal endocervical glands. TLR9 expression, which was mainly observed as cytoplasmic staining, gradually increased in accordance with the histopathological grade in the following order: chronic cervicitis (2/17, 11.8%) <CINI (4/19, 28.6%) <CINII (3/10, 30.0%) <CINIII (12/24, 50.0%) <CSCC (17/32, 53.1%) (p<0.05), but not with tumor differentiation. RT-PCR and Western blotting showed that TLR9 expression was up-regulated in HPV16 E6 and E7 silenced SiHa cells at both mRNA and protein levels.
CONCLUSIONS: TLR9 expression increases according to the histopathological grade of cervical pathological process. HPV E6 and E7 oncoprotein have negative effects on the expression and function of TLR9.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25081715     DOI: 10.7314/apjcp.2014.15.14.5867

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

1.  TLR9 gene polymorphism -1486T/C (rs187084) is associated with uterine cervical neoplasm in Mexican female population.

Authors:  Cecilia Martínez-Campos; Margarita Bahena-Román; Kirvis Torres-Poveda; Ana I Burguete-García; Vicente Madrid-Marina
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-17       Impact factor: 4.553

2.  Fas and Fas ligand are highly expressed in lymphocytes from cervical intraepithelial neoplasia and cervical cancer patients: A possible role for immune escaping.

Authors:  Carla O Contreras-Ochoa; Margarita Bahena-Román; Luz Yvette López-Díaz; Alfredo Lagunas-Martínez; Carlos Mojica-Cardoso; Joaquín Manzo-Merino; Kirvis Torres-Poveda; Vicente Madrid-Marina
Journal:  Iran J Basic Med Sci       Date:  2022-03       Impact factor: 2.532

Review 3.  HPV disease transmission protection and control.

Authors:  Neil D Christensen
Journal:  Microb Cell       Date:  2016-09-05

4.  Mutation differences in circulating tumor DNAs from non-small cell lung cancer patients between Uygur and Han populations.

Authors:  Yuli Wang; Jing Li; Jian Huang; Chaoqun Wu; Li Li; Ping Gong
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

Review 5.  The Associations between Toll-Like Receptor 9 Gene Polymorphisms and Cervical Cancer Susceptibility.

Authors:  Sijuan Tian; Liping Zhang; Ting Yang; Xing Wei; Li Zhang; Yang Yu; Yang Li; Di Cao; Xiaofeng Yang
Journal:  Mediators Inflamm       Date:  2018-07-25       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.